Journal of Clinical Oncology
Journal Abbreviation: J CLIN ONCOL
ISSN: 0732-183X
eISSN: 1527-7755
Publisher: American Society of Clinical Oncology
Publications (55)
Neoadjuvant trastuzumab emtansine and pertuzumab in human epidermal growth factor receptor 2–positive breast cancer: Three-year outcomes from the phase III KristinE study (2019)
Hurvitz SA, Martin M, Jung KH, Huang CS, Harbeck N, Valero V, Stroyakovskiy D, et al.
Journal article
Role of Donor Clonal Hematopoiesis in Allogeneic Hematopoietic Stem-Cell Transplantation (2019)
Frick M, Chan W, Arends CM, Hablesreiter R, Halik A, Heuser M, Michonneau D, et al.
Journal article
Pretreatment Vitamin D deficiency is associated with impaired progression-free and overall survival in hodgkin lymphoma (2019)
Borchmann S, Cirillo M, Goergen H, Meder L, Sasse S, Kreissl S, Broeckelmann PJ, et al.
Journal article
Selumetinib in combination with dacarbazine in patients with metastatic uveal melanoma: A Phase III, Multicenter, Randomized Trial (SUMIT) (2018)
Carvajal RD, Piperno-Neumann S, Kapiteijn E, Chapman PB, Frank S, Joshua AM, Piulats JM, et al.
Journal article
Phase III Randomized Study of Ribociclib and Fulvestrant in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: MONALEESA-3 (2018)
Slamon DJ, Neven P, Chia S, Fasching P, De Laurentiis M, Im SA, Petrakova K, et al.
Journal article
BRCA1/2 Mutations and Bevacizumab in the Neoadjuvant Treatment of Breast Cancer: Response and Prognosis Results in Patients With Triple-Negative Breast Cancer From the GeparQuinto Study (2018)
Fasching P, Loibl S, Hu C, Hart SN, Shimelis H, Moore R, Schem C, et al.
Journal article
Survival Analysis After Neoadjuvant Chemotherapy With Trastuzumab or Lapatinib in Patients With Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer in the GeparQuinto (G5) Study (GBG 44) (2018)
Untch M, Von Minckwitz G, Gerber B, Schem C, Rezai M, Fasching P, Tesch H, et al.
Journal article
Eosinophil-cationic protein: A novel liquid prognostic biomarker in melanoma (2018)
Moreira A, Krueckel A, Schuler G, Heinzerling L
Conference contribution
Can checkpoint inhibitor therapy improve response to chemotherapy? (2017)
Boßerhoff AK, Schuler G, Heinzerling L, Schilling B, Haferrkamp S, Kirchberger M
Conference contribution, Conference Contribution
CONKO-005: Adjuvant Chemotherapy With Gemcitabine Plus Erlotinib Versus Gemcitabine Alone in Patients After R0 Resection of Pancreatic Cancer: A Multicenter Randomized Phase III Trial (2017)
Sinn M, Bahra M, Liersch T, Gellert K, Messmann H, Bechstein W, Waldschmidt D, et al.
Journal article